If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Institute of Human Genetics, Faculty of Medicine, Technical University München, Munich, Germany;Institute of Human Genetics, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany;Institut für Neurogenomik, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany;
Barrow Neurological Institute, Phoenix Children’s Hospital, Phoenix, AZ, USADepartments of Child Health, Neurology, Cellular & Molecular Medicine and Program in Genetics, University of Arizona College of Medicine, Phoenix, AZ, USA;
Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Melbourne, VIC, Australia;Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia;
Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Melbourne, VIC, Australia;Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia;
Barrow Neurological Institute, Phoenix Children’s Hospital, Phoenix, AZ, USADepartments of Child Health, Neurology, Cellular & Molecular Medicine and Program in Genetics, University of Arizona College of Medicine, Phoenix, AZ, USA;
Institute of Human Genetics, Faculty of Medicine, Technical University München, Munich, Germany;Institute of Human Genetics, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany;University Childrens Hospital, Paracelsus Medical University, Salzburg, Austria;
Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France;Neuroscience Department, Human Genetics and Cognitive Function Unit, Pasteur Institute, Paris, France
TNR, encoding Tenascin-R, is an extracellular matrix glycoprotein involved in neurite outgrowth and neural cell adhesion, proliferation and migration, axonal guidance, myelination, and synaptic plasticity. Tenascin-R is exclusively expressed in the central nervous system with highest expression after birth. The protein is crucial in the formation of perineuronal nets that ensheath interneurons. However, the role of Tenascin-R in human pathology is largely unknown. We aimed to establish TNR as a human disease gene and unravel the associated clinical spectrum.
Methods
Exome sequencing and an online matchmaking tool were used to identify patients with biallelic variants in TNR.
Results
We identified 13 individuals from 8 unrelated families with biallelic variants in TNR sharing a phenotype consisting of spastic para- or tetraparesis, axial muscular hypotonia, developmental delay, and transient opisthotonus. Four homozygous loss-of-function and four different missense variants were identified.
Conclusion
We establish TNR as a disease gene for an autosomal recessive nonprogressive neurodevelopmental disorder with spasticity and transient opisthotonus and highlight the role of central nervous system extracellular matrix proteins in the pathogenicity of spastic disorders.
While in the past disease entities were primarily described based on specific clinical findings, the rapidly evolving sequencing technologies have added a new dimension of entities based on genetic diagnoses. A combination of both has characterized syndromes such as hereditary spastic paraparesis
However, genetic diagnostics in diseases that do not fit into any of the established categories is difficult and often requires interdisciplinary approaches and the inclusion into research projects.
Perineuronal nets constitute a specialized form of the extracellular matrix (ECM) that are composed of the proteogylcans aggrecan, neurocan, and brevican as well as hyaluronan.
TNR encodes Tenascin-R, a member of the tenascin family of ECM glycoproteins, which is crucial for the crosslinking of proteoglycan hyaluronan complexes.
TNR is exclusively expressed in the central nervous system with the exception of a transient expression in Schwann cells during peripheral nerve development.
Tenascin-R is involved in neurite outgrowth, neural cell adhesion, proliferation and migration, fate determination, axonal guidance, myelination, synaptic plasticity, and modulation of sodium channel function.
During fetal development, Tnr−/− mice display increased numbers of GABAergic interneurons. TNR deficiency has been found to be involved in the regulation of neuronal differentiation at least in the mouse dentate gyrus.
The broad variety of findings in the mouse model constitutes TNR as an excellent candidate gene for neurogenetic disease. Indeed, two recent reports have identified cases with biallelic loss-of-function (LoF) variants in TNR. The first patient was born from consanguineous Lebanese parents and presented with intellectual disability and early onset opisthotonic posture (at 4–6 weeks of age); array comparative genomic hybridization identified a homozygous deletion containing all protein coding regions of TNR as well as parts of the 5′-untranslated region of KIAA0040 allowing authors to suggest TNR’s implication in brain development and cognition.
The second patient was described in a case series of 100 adults with leukoencephalopathy. Exome sequencing revealed a homozygous LoF variant in TNR (c.1475delG, p.[Arg492Profs*45]) in a Turkish female who developed a floppy head and opisthotonic spasms of her neck and back, generalized dystonia, and spasticity at three months and had mild learning difficulties.
Here, we report 13 patients from 8 unrelated families with biallelic variants in TNR causing a complex syndrome characterized by mild neurodevelopmental delay, axial muscular hypotonia, spasticity, hypokinesia, and transient opisthotonus establishing TNR as a disease gene for spastic para- or tetraparesis.
MATERIALS AND METHODS
Patients and samples
All patients or their parents gave written informed consent for the pseudonymized clinical data collection, collection and storage of biological samples, experimental analyses, and the publication of relevant findings and images/videos. The study was performed in agreement with the Declaration of Helsinki and approved by the Ethical Committees of the centers participating in this study (Munich, Germany; Hamburg, Germany; Paris, France; Phoenix, AZ, USA; Sao Paulo, Brazil; and London, UK). Percentiles for growth parameters were estimated for all individuals as previously described.
Exome sequencing (ES) and TNR Sanger sequencing was carried out independently at five different centers using genomic DNA extracted from leukocytes. Technical details can be found in Supplementary Table 1.
Table 1Clinical information of individuals identified with biallelic variants in TNR.
Separate models were created for individual domains using separate Protein Data Bank (PDB) files as templates. Fibronectin domain 1 was modeled on PDB file 3TEU (38% sequence identity, 105 residues).
The C-terminal fibrinogen domain was modeled on PDB file 6QNV (61% sequence identity, 231 residues). Additionally, Fibronectin domain 3 was available as PDB file 1TDQ.
In brief, 13 patients from 8 unrelated families (7 males, 6 females, current ages ranging from 1 to 24 years; pedigrees can be found in Fig. 1) were referred for evaluation of developmental delay after uneventful pregnancy, delivery, and postnatal adaptation in most families (see Supplementary case reports). They originated from consanguineous families from Turkey, Morocco, Saudi Arabia, Iraq, and Brazil as well as a nonconsanguineous family from India. No dysmorphic features were noted.
Fig. 1Identification of biallelic TNR variants in eight families.
Pedigrees of the families (families A–H) in whom exome sequencing identified biallelic variants in TNR segregating with the disease. Black filled symbols represent affected individuals whereas open symbols represent unaffected family members. +/+ indicates that variants were identified in homozygosity; +/− are heterozygous carriers. No variants in TNR were identified in individuals marked with −/−.
Detailed assessment of patients’ history revealed that motor developmental milestones were delayed in all patients: unsupported sitting was achieved at a median age of 12 ± 9 months and standing without hold at a median age of 35 ± 12 months. Free standing was not achieved at all in four children. Five of 11 (45%) patients showed transient opisthotonic posturing during the first year of life. Cognitive development was mildly or moderately impaired in 6 of 13 patients (46%) as judged by the caring physician, however, there is no formal neuropsychological testing available. Four of 11 patients did not have cognitive developmental delay and two cases were too young for a reliable evaluation. Most patients showed delayed language development (12/13; 92%). However, language impairment was variable, with patient 7 speaking fluently from the age of five years onward, whereas patient 6 still had severe expressive language impairment at the age of eight years, with concomitant dysarthria.
During the assessment of the current neurological status at the median age of 5 years (range 2–24 years) patients typically presented with a spastic tonus dysregulation of two or four extremities (10 affected/12 examined; 83%) with axial hypotonia (8/12; 67%). Lower limb deep tendon reflexes were normal in two patients and increased in all other examined patients (10/12; 83%), 7 patients (7/12; 58%) had increased upper limb reflexes. Notably, all patients were very friendly (happy demeanor) in their interaction with their environment, which was not related to lack of stranger anxiety as observed in children with autism and we did not observe inappropriate laughter. Dyspraxia was noted as a further neurological symptom in 7/13 (54%) patients. In addition to spastic para- or tetraparesis, also (oromandibular) dystonia (7/13; 54%), choreoathetosis and parkinsonism could be documented. Cerebellar symptoms were not observed in our patients. The three oldest patients (age >12 years) included in our study as well as the case reported
largely caught up the delay in cognitive and motor development after infancy, as reported by the responsible clinicians. Moreover, none of our patients developed additional neurological system involvement over time and the severity of the neurological symptoms did not increase over time. Spasticity neither improved nor deteriorated. This indicates that TNR-associated disease is nonprogressive in nature.
MRI findings in TNR-related disease
Brain magnetic resonance imaging (MRI) was performed in 11/13 patients. Relevant images or whole MRI data sets have been evaluated by the same pediatric neuroradiologist.
Delayed myelination was observed in four cases: patients 1, 3, 5, and 9 at the age of 4 months, 1 year 7 months (Fig. 2a), 10 months, and 2 years 8 months (Fig. 2d), respectively. In patient 3 the delayed myelination of the temporal subcortical white matter was persistent at the age of five years (Fig. 2b) compared with a brain MRI of a normal five-year-old boy (Fig. 2c). In contrast, myelination appeared normal on follow-up at two years in patient 1, which is in line with the clinical evaluation, where symptom severity remained stable or even showed slight improvements over time.
Fig. 2Magnetic resonance image (MRI) findings in TNR-related neurodevelopmental disease.
(a) and (b) Coronal T2-weighted cerebral MRI images of patient 3 at the age of 1 year and 7 months (a) and a follow-up at 5 years (b). (a) Temporal subcortical white matter is not yet myelinated at 1 year 7 months (thin white arrows). (b) MRI revealed a persistent white matter T2 hypersignal at 5 years showing that myelination of the temporal region was not achieved (thin white arrows). (c) Healthy control MRI that was done at age 5 years showing complete myelination of the temporal region. (d) Axial fluid-attenuated inversion recovery (FLAIR) weighted sequence of patient 9 at 2 years 8 months, showing a subcortical white matter hypersignal consistent with uncompleted myelination. (e) T1-weighted median sagittal MRI section of patient 11 showing a partial posterior corpus callosum agenesis (large white arrow).
In two cases, MRI revealed corpus callosum abnormalities: patient 6 had a thin corpus callosum and patient 11 had an agenesis of the posterior part of the corpus callosum associated with a splenium agenesis at the age of 10 months (Fig. 1e). Brain MRI was considered to be normal in patients 2, 4, 7, 12, and 13. Cerebellar abnormalities were not found in any of our cases.
Biallelic variants in TNR
In all index patients, exome sequencing at the local genetic centers did not identify causative variants in established disease genes. Filtering for rare (minor allele frequency [MAF] <0.5% in the respective in-house databases) protein altering variants identified biallelic variants in TNR (NM_003285.2) in index patients from all families. Additional potentially biallelic variants identified in the index cases by exome sequencing can be found in the Supplementary Information. Segregation by Sanger sequencing did support TNR as a candidate gene. A web-based collaboration platform, GeneMatcher,
established the collaboration presented here. Pedigrees and the identified variants can be found in Fig. 1.
A total of four LoF and four missense variants were detected. Patient 1 had a homozygous nonsense variant c.2713C>T, p.(Arg905*); patient 2 had a homozygous frameshift alteration c.2744_2745delTG; p.(Val915Aspfs*64). The LoFs c.1899delT p.(Glu634Serfs*20) and c.207C>G; p.(Tyr69*) were identified in patient 6 and patients 9 and 10 (family F) respectively.
In the four other families, two homozygous and two compound heterozygous missense variants were identified: in family C (patients 3–5), the variant c.3574C>T is predicted to result in the substitution of a highly conserved C-terminal amino acid position of the fibrinogen-like domain with to date unknown function, p.(Arg1192Trp). Of note, the C-terminal is not affected by the proteolytic cleavage of the 180-kDa TNR protein into the 160-kDa isoform and therefore the variant should be expressed.
The same variant was identified in the index patient of family E (patient 7) and confirmed by Sanger sequencing in the elder sister (patient 8). In the index patient of family G (patient 11), the missense variant c.3357C>G; p.(Ser1119Arg) was found which is located in the C-terminally Fibronectin type III 9 domain, which is also not affected by proteolytic cleavage. The variants c.1189G>A and c.1594G>A (p.[Asp532Asn] and p.[Ala397Thr]) were identified in patient 13 from family H in a compound heterozygous state as determined be segregation analysis using Sanger sequencing. A graphical view of the TNR transcript structure and the protein product as well as the location of the eight novel and one previously published variants can be found in Fig. 3. Variant details including in silico predictions as well as conservation scores can be found in Supplementary Table 2.
Fig. 3Graphical view of the location of the eight variants identified with respect to transcript structure and protein product as well as 3D modeling of missense variants.
(a) TNR encodes a 21-exon transcript (NM_003285.2). The protein encompasses an N-terminal epidermal growth factor–like domain depicted in orange, nine fibronectin type III domains displayed as blue boxes, and a C-terminal Fibrinogen-like domain colored in green. The arrows and dotted lines mark the positions of the published and novel variants. (b–e) 3D modeling of the missense variants. The mutant amino acid is displayed in magenta, α-helices are depicted in blue, β-strands in red, and loops in cyan. (b) The variant p.(Ala397Thr) is located in fibronectin domain 1, where the mutated alanine is buried in the core. Mutation of this small and hydrophobic residue into a slightly larger one with an extra hydrophilic sidechain is predicted to affect the local structure. (c) The variant p.(Asp532Asn) occurs on the surface of fibronectin domain 3. The sidechains of both amino acids have the same size and both are hydrophilic. However, aspartate is negatively charged whereas asparagine is neutral. The variant might affect interaction with brevican in the formation of perineuronal nets. (d) The variant p.(Ser1119Arg) occurs on the surface of fibronectin domain 9. However, whereas serine is small and neutral, arginine is large and positively charged. This could affect any interactions made on the surface of this domain. (e) The variant p.(Arg1192Trp) is located in the fibrinogen domain at the C-terminus. The arginine at this position is necessary for hydrogen bonds that stabilize the structure. Mutation into the large and hydrophobic sidechain of tryptophan is predicted to affect the local structure.
and could not be identified in population-specific databases focused on Middle Eastern ethnicities, i.e., GME variome database (http://igm.ucsd.edu/gme/)
To better understand the pathophysiologic mechanism of missense variants we performed 3D modeling of the respective variants (Fig. 3b–e). The variant p.(Ala397Thr) is predicted to affect the local structure whereas the variant p.(Asp532Asn) might affect interaction with brevican in the formation of perineuronal nets. The variant p.(Ser1119Arg) is located on the surface of the fibronectin 9 domain most likely impairing interactions made on the surface of this domain. p.(Arg1192Trp) is located in the fibrinogen domain at the C-terminus and is predicted to affect the local structure.
DISCUSSION
We report biallelic variants in TNR encoding the ECM protein Tenascin-R in 13 affected individuals from 8 families. The phenotype encompasses a complex neurological disorder characterized by developmental delay with spastic para- or quadriparesis, axial muscular hypotonia, hypokinesia, and transient opisthotonus combined with a happy demeanor and habitus. Moreover, less frequently observed were language problems. Movement disorders (dystonia, parkinsonism) indicate affection of the extrapyramidal motor system in TNR-related disease. While the cardinal clinical features did not differ significantly between the eight families, the grades of phenotypic severity varied to a greater extent. These differences might be explained by the excess of homozygous variants in our consanguineous families (rare biallelic variants can be found in the Supplementary Information).
Brain MRIs revealed cerebral abnormalities in 6 of 11 patients for whom MRIs were available (65%). This included delayed myelination in four and corpus callosum abnormalities in two cases. The cerebellum was normal in all cases. Given that delayed myelination and corpus callosum hypoplasia are rather unspecific findings, we could not establish a consistently recognizable MRI phenotype. Intrafamilial heterogeneity as assessed in families C and G was considerable with individuals having both normal and pathologic MRIs at comparable ages within individual pedigrees.
The observations, i.e., that none of our patients developed novel neurological system involvement over time and that the MRI findings improved in follow-up investigations, argue against a neurodegenerative aspect and indicate a nonprogressive nature of the disorder.
It is difficult to delimit TNR-associated disease from complicated hereditary spastic paraplegia (HSP), which is characterized by progressive lower limb spasticity and weakness in combination with additional neurologic features such as cognitive deficits, movement disorder, or neuropathy. However, based on the core phenotype, i.e., the spastic affection of both upper and lower limbs as well as this nonprogressive nature of the symptoms, we regard TNR-related disease as different from HSP.
So far, only two homozygous variants—a frameshift variant, c.1475delG, p.(Arg492Profs*45), and a homozygous 1q25.1 deletion including TNR—have been reported, suggesting TNR as a candidate gene. Both variants were associated with a neurological phenotype that included spastic quadriparesis, intermittent opisthotonic spasms in the first months of life, delayed motor milestones, dystonia, axial hypotonia, and hyperreflexia, thus resembling the phenotype of our study population (Table 1).
Heterozygous LoF variants in TNR are rare (40 in >280,000 alleles) and homozygous variants absent are in gnomAD, indicating that biallelic pathogenic variants in TNR are likely to cause disease.
We identified four different LoF variants (nonsense and frameshift) in four families as well as four missense variants— c.1189G>A; p.(Ala397Thr), c.1594G>A; p.(Asp532Asn), and c.3357C>G; p.(Ser1119Arg) as well as c.3574C>T; p.(Arg1192Trp)—that we identified in two unrelated families. The latter was found in a family from Iraq and Morocco and is absent from control databases. The missense variants are located in the C-terminal fibrinogen-like domain and the fibronectin type III 9 domain, a domain with unknown function to date. There was no significant clinical difference between individuals with LoF and missense variants that would imply a genotype–phenotype correlation indicating a LoF character of the missense variants.
These findings define a novel form of a neurodevelopmental disease presenting with early onset nonprogressive spasticity and developmental delay.
Interestingly, the patient reported by Lynch et al.
carrying the variant c.1475delG, p.(Arg492Profs*45) had a similar phenotype as the individuals identified in our study, but was diagnosed with multiple sclerosis (MS) at the age of 19 due to several T2/FLAIR periventricular white matter, brainstem and cerebellum hyperintensities, and the presence of oligoclonal bands in cerebrospinal fluid (CSF). We believe that, since none of the individuals reported in the present study had MS-like MRI or CSF findings, the published patient potentially was suffering from both TNR-associated neurodevelopmental disease and concomitant MS and that the oligoclonal bands were not associated with the variant in TNR.
TNR is highly expressed in oligodendrocyte precursors with a decreased expression during oligodendrocyte differentiation, suggesting a functional role during myelination.
This might explain why 40% of our cases had delayed myelination as abnormal MRI findings. TNR is also expressed in type 2 astrocytes and few neuronal cells in the spinal cord, retina, cerebellum, and hippocampus, especially in perineuronal nets surrounding inhibitory interneurons.
a disruption of synaptic plasticity could explain the neurodevelopmental phenotype in our patients. The spatiotemporal expression pattern with the highest expression of TNR in the developing brain is in line with the observed nonprogressive nature of the disease. Even though the behavioral phenotype of TNR-deficient mice does not resemble the symptoms observed in our patients, the mouse model clearly indicates that loss of TNR results in a neurodevelopmental defect.
To date, perineuronal nets or central nervous system ECM proteins have not been implicated in the pathogenesis of spastic disorders, but their dysfunction or loss has been observed in Alzheimer disease, fragile X syndrome, and schizophrenia.
The identification of novel disease genes often reveals disease-associated molecular mechanisms. Establishing TNR as a disease gene is the first link of central nervous system ECM proteins and perineuronal nets to the pathogenesis of neurodevelopmental disorders.
In conclusion, TNR deficiency causes an early onset and nonprogressive neurodevelopmental disorder characterized by axial hypotonia, spasticity, developmental delay, hypokinesia, and transient opisthotonus.
Data availability
The authors declare that the data supporting the findings of this study are available within the article and its supplementary material. Raw sequencing data are available from the corresponding authors on request if in line with the provided consent of the families.
Y.C.S. is an employee of GeneDx, Inc. The other authors declare no conflicts of interest.
Acknowledgements
We thank the patients and their families for participation in this study. We thank the Helmholtz-Zentrum Munich NGS core facility, especially Elisabeth Graf and as well as Gertrud Eckstein, Peter Lichtner, and Veronika Schwarzbauer for their excellent support. We also thank the Robert-Debré University Hospital for its full support. We also thank Fikret Yüzgülen for referring his patient. We thank Martin Krenn for his revision of the manuscript. This study was partly funded by Dietmar Hopp Stiftung (St. Leon-Rot, Germany) and the CNRG (Centre National de Génotypage (JFDeleuze).
Author Contributions
These authors contributed equally: Matias Wagner, Jonathan Lévy, Sabine Jung-Klawitter
These authors contributed equally: Anne-Claude Tabet, Thomas Opladen
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
00839-X&id=gr1.jpg){kind=link}
00839-X&id=gr2.jpg){kind=link}
00839-X&id=gr3.jpg){kind=link}